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ABSTRACT
Pediatric pulmonary hypertension (PH) is a
heterogeneous disorder that leads to significant
morbidity and mortality if left untreated. The
Nice WHO classification from 2013 classifies PH
into five groups: broadly, Group I pulmonary
arterial hypertension (PAH), which includes
idiopathic PAH, PAH associated with congenital
heart disease and others; Group II comprises
post-capillary PH (left heart disease), Group III
comprises lung disease, Group IV thromboem-
bolic disease and Group V miscellaneous causes
of PH. The majority of pediatric PH comprise
either Group I or Group III PH, but often chil-
dren manifest features of several groups and are
treated with targeted therapy. PAH in children
requires a multifaceted approach. The patho-
genesis is complex and it involves pulmonary
vasoconstriction, endothelial dysfunction,
inflammation and cell proliferation. Large
multicenter and international registries have
been formed with the aim of furthering under-
standing of this disease and developing
appropriate therapeutic guidelines for manag-
ing pediatric PH. In this review, we describe the
epidemiology, pathophysiology, clinical pre-






Pediatric pulmonary arterial hypertension
(PAH) is recognized as a progressive and fatal
illness. There have been multiple advances in
the field within the last two decades aimed at
prolonging survival rates and improving quality
of life. Despite all these efforts, PAH still
remains an important cause of morbidity and
mortality in children [1–3].
Pulmonary hypertension is estimated to
affect\10 cases per million children, with an
incidence of 1–2 new cases/million per year.
There are multiple registries around the world
that have included children and adults with
PAH. The Tracking Outcomes and Practice in
Pediatric Pulmonary Hypertension (TOPP) reg-
istry is a global, prospective study designed to
provide information about demographics,
treatment, and outcomes in pediatric pul-
monary hypertension [4]. In the United States,
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the Registry to Evaluate Early And Long-Term
PAH Disease Management (REVEAL) registry is a
multicenter, observational study which inclu-
ded 216 patients\18 years of age with Group I
pulmonary arterial hypertension (PAH): 56% of
these patients were affected by idiopathic PAH
and familial PAH with slight female predomi-
nance (60%), 36% were associated with con-
genital heart disease (APAH-CHD) and 8% were
associated with other causes of PAH such as
connective tissue disease (CTD), portal hyper-
tension and persistent pulmonary hypertension
of the newborn (PPHN) [5].
The overall outlook for PAH has dramatically
improved over the last two decades since the
discovery of epoprostenol in 1976, a synthetic
prostacyclin that was finally approved for the
treatment of PAH in 1995 leading to a signifi-
cant improvement in survival rates [6–8]. Early
reports of children affected with PAH showed a
median survival of only 10 months [9]. In the
modern era, with early diagnosis and initiation
of therapy, survival at 1, 2 and 3 years has been
reported to be 99%, 96% and 84% in children
with PAH [10]. Patients with Eisenmenger syn-
drome (ES) have better survival compared to
IPAH with most ES patients surviving into their
third–fourth decade, most likely due to the
presence of a pop-off shunt [11]. The right
ventricle (RV) in ES is subjected to systemic
pressures from birth as the pulmonary vascular
resistance (PVR) never regresses to normal
levels. Thus, the RV musculature appears to
adapt to high pressures (similar to fetal life) and
remains capable of sustaining its systolic func-
tion despite pumping against high PVR for
much longer than in IPAH where the RV is
subject to elevated PVR much later, and hence
fails earlier than in patients with ES [12].
Continuous efforts are being made to bring
awareness of the disease leading to early diag-
nosis, decreased morbidity and improved sur-
vival. Pediatric patients across North America
are being enrolled in the Pediatric Pulmonary
Hypertension Network (PPHNET) Informatics
Registry, a pediatric clinical registry that will
include a large number of children with PH.
This will lead to improved understanding of
childhood PH and help guide therapy. Novel
translational research ideas that focus on the
molecular and genetic basis of PH are being
studied which will clarify the pathogenesis of
the disease and also assist in tailoring therapy
based on the genetic changes as well as devel-
oping newer targeted therapies with greater
efficacy for the treatment of PAH [13–15].
The main focus of this review will be on
Idiopathic Pulmonary Arterial Hypertension
(IPAH), reviewing current available therapies
and those undergoing investigation. We must
acknowledge that many pediatric patients have
characteristics of different WHO groups of PH
and may not wholly fit into one group. For the
purposes of this review, other major causes of
PH such as congenital heart disease, connective
tissue disorder and parenchymal lung disease
will be excluded.
This article is based on previously conducted
studies and does not involve any new studies of
human or animal subjects performed by any of
the authors. In this report, the authors discuss
several medications and therapies which are not
FDA-approved for pediatric use, and use of these
medications for pediatric patients is to be done
only at centers with experience and expertise
for caring for these patients.
DEFINITION
Pulmonary arterial hypertension (PAH) in chil-
dren is defined as a resting mean pulmonary
artery pressure (mPAP) C25 mmHg with pul-
monary arterial wedge pressure
(PAWP)\15 mmHg and pulmonary vascular
resistance indexed (PVRI)[3 woods units 9m2
in patients with two ventricles [15]. Blood
pressure in children also varies with age com-
pared to adults, and as a result a pulmonary to
systemic pressure ratio of[0.4 is also considered
indicative of PAH [16]. PAH is particularly
challenging due to its multifactorial nature and
it can often be the common denominator of
multiple conditions. The updated WHO clinical
classification demonstrates the diversity and
complexity of pediatric pulmonary hyperten-
sion [17].
Most children with PH belong to WHO
Group I, II and III PH with fewer thromboem-
bolic or multifactorial (Group IV or V) PH.
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Pulmonary arterial hypertension (PAH) is a
synonym of ‘‘pre-capillary’’ pulmonary hyper-
tension and encompasses IPAH and associated
PAH (APAH) secondary to congenital heart dis-
ease (CHD), connective tissue disease (CTD) and
persistent pulmonary hypertension of the
newborn (PPHN) are included in Group 1 PH
[18]. Unlike the adult population in which CTD
and left ventricular diastolic dysfunction (WHO
Group II) are important causes of PH, in chil-
dren, IPAH/HPAH, congenital heart disease
(CHD) and chronic lung disease (CLD) are more
frequent causes of PH. This is also exponentially
changing, as more patients with CHD survive
into adulthood [19, 20].
PATHOGENESIS OF PEDIATRIC PAH
Genetic predisposition to hereditary PAH was
first reported in 1954 [21], and since then,
multiple genes have been discovered and asso-
ciated with PAH [22–25] (Table 1). HPAH has an
autosomal dominant mode of inheritance with
the defect in most cases localized to a region on
chromosome 2q31–33 [26, 27]. The transform-
ing growth factor B (TGFB) family of receptors
has been studied extensively, particularly the
bone morphogenic protein receptor (BMPR2)
associated with HPAH [28–30]. BMPR2 muta-
tions are seen in over 80% of patients with
HPAH, being up to 25% de novo mutations.
Interestingly, only about 20% of subjects with a
BMPR2-detected mutation develop the disease
and the clinical presentation is variable even
within the same family. There is a higher inci-
dence of HPAH in females compared to males,
leading to speculation that the male fetuses
might die in utero [31–33]. Furthermore, sex
hormones can modulate NO signaling pathways
and circulating endothelin-1 levels. Alteration
in estrogen metabolism is linked to increased
risk of PAH penetrance in female, but not male,
BMPR2 carriers. On the other hand, men with
IPAH/HPAH have higher estradiol and low
dehydroepiandrosterone sulfate levels which
have has been associated with disease severity
[34].
Channelopathies have also been described in
IPAH and HPAH. KCNK3, a potassium channel
that is sensitive to hypoxia, plays an important
role in pulmonary vascular tone. Heterozygous
mutation of KCNK3 is associated with regula-
tion of vascular remodeling and abnormal vas-
cular proliferation of pulmonary vessels [35].
Other mutations such as activin receptor-like
kinase 1 (ALK-1) located in chromosome 12 and
endoglin (ENG) on chromosome 9 have been
described in patients with hereditary hemor-
rhagic telangiectasia (HHT) and HPAH [36]. The
SMAD8 gene on chromosome 13, which is
involved in the TGF-beta/BMP signaling, has
also been associated in patients with PAH [37].
Caveolin (CAV-1) gene mutation has also been
recently reported in association with activation
of proliferative and anti-apoptotic pathways
leading to vascular injury [38, 39]. Genetic
testing can be useful in children with IPAH or in
families with HPAH to allow for definition of
etiology and identification of family members
at risk to be able to best counsel the family [40].
Testing should start with the proband and
family members should be tested for the muta-
tion expressed in the affected patient [15, 41].
IPAH can present in the neonatal period or
infancy, and is often diagnosed and treated as
persistent pulmonary hypertension of the
newborn (PPHN). For this reason, when PAH
persists beyond the first few weeks of life, one
must suspect early presentation of IPAH. In
these children, lung histopathology is very
similar to changes seen in IPAH at an older age
[42].
The progression and phenotypic variability
of PAH may be affected by multifactorial factors
such as genetic background, epigenetic changes,
gender and other extraneous factors such as
infection and inflammation. Genetically sus-
ceptible individuals are more likely to progress
into the classic phenotype. Epigenetic modifi-
cations may aggravate the disease severity.
Three main types of epigenetic regulation
involving DNA methylation, histone modifica-
tion and microRNA (miRNA) have been descri-
bed in the pathogenesis of PAH [43]. The exact
mechanism of the pathogenesis of PAH has not
been completely elucidated. Its complexity
involves imbalance of vasogenic mediators
leading to vasoconstriction, endothelial cell
dysfunction, smooth muscle cell proliferation,
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altered mechanisms of apoptosis, inflamma-
tion, thrombosis and molecular deviations, as
shown in Fig. 1. As more elements involved in
this complex process are uncovered, further
innovative studies are being carried out in ani-
mal and cellular models [44, 45].
Endothelial Dysfunction
The endothelium is vital for maintaining vas-
cular tone, homeostasis, leukocyte trafficking,
transduction of luminal signals to abluminal
vascular tissues, production of growth factors,
and cell signals with autocrine and paracrine
effects and barrier function. Endothelial dys-
function leads to exposure of different cytoki-
nes into the vascular wall, leading to humoral
imbalance, endothelial cell proliferation and
increased coagulability, resulting in medial
hypertrophy and hyperplasia [46].
Cell Proliferation and Apoptosis
More attention has been directed towards cell
growth compared to vasoconstriction alone as
we gain more knowledge in molecular biology.
Table 1 Genetic mutations associated with PAH
Gene Name Specialized Information
BMPR2 TGF-breceptor superfamily member
C80% of familial cases
15–25% of IPAH cases
ALK1 TGF-breceptor superfamily member
PAH associated with familial HHT
Not known to occur distinct from HHT
Endoglin TGF-b receptor superfamily member
PAH associated with familial HHT
Not known to occur distinct from HHT
SMAD9 TGF-b superfamily downstream signaling molecule (canonical signaling pathway)
Encodes SMAD8
CAV1 Encodes caveolin-1, relevant to caveolar structure as well as nitric oxide signaling
Exact estimate of frequency among PAH patients yet to be determined
KCNK3 Encodes TASK-1, a pH sensitive potassium channel
Exact estimate of frequency among PAH patients yet to be determined
EIF2AK4 (GCN2) Association with recessive and sporadic forms of PVOD and PCH
Encodes a eukaryotic translation initiation factor superfamily member
Exact estimate of frequency among PVOD and PCH patients yet to be determined
Adapted from [39]
All genes are associated with autosomal dominant familial disease except for EIF2AK4, which is associated with autosomal
recessive PVOD and PCH
HHT hereditary hemorrhagic telangiectasia; IPAH idiopathic pulmonary arterial hypertension; PAH pulmonary arterial
hypertension; PCH pulmonary capillary hemangiomatosis; PVOD pulmonary veno-occlusive disease; and TGF-b trans-
forming growth factor-b
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Many substances, including serotonin (5-HT),
platelet-derived growth factor (PDGF), epider-
mal growth factor (EGF), and vascular
endothelial growth factor (VEGF) have direct
associations with abnormal cell proliferation
and migration of pulmonary artery vascular
cells, playing an important role in vascular
remodeling. Mutations in BMPR2, ALK-1 and
endoglin are also associated with vascular
remodeling [47]. Damage to endothelial cells
triggers apoptotic mechanisms leading to
mature vascular lesions composed of endothe-
lial cells, smooth muscle cells and apoptotic
cells. Endothelial and SMCs also demonstrate
mitochondrial abnormalities in PAH patients,
which lead to a shift in metabolism favoring
Fig. 1 Some cellular processes implicated in the patho-
genesis of primary PH (PPH). Extracellular mediators and
cells (platelets) are highlighted in yellow, cell surface
receptors and ion channels in purple, intracellular signaling
in blue, and nuclear responses in green. VEGF indicates
vascular endothelial growth factor; its receptor is KDR.
Intracellular transduction of this pathway is poorly
understood. Endothelin is vasoactive and a mitogen, acting
through Ca2 channels and ERK/Jun kinases. TIE is the
angiopoietin receptor, a system found to be upregulated in
pulmonary vascular disease. Alk1 and BMPR1-2 are
receptors of the TGF-b superfamily, and BMP indicates
bone morphogenetic protein. Alk1 mutations cause
hereditary hemorrhagic telangiectasia and some cases of
PPH. Epidermal growth factor (EGF), tumor necrosis
factor (TNF)-a, angiotensin II (ANGII), and platelet-der-
ived growth factor (PDGF) are all proliferative stimuli that
act through tyrosine kinase receptors and are partially
transduced by intracellular oxidant species. In the intra-
cellular domain, SMADs are regulatory proteins that
activate nuclear transcription factors and interact with
MAP kinases. AML1 is a nuclear transcription factor of
potential importance. Elastase, downstream of AML1, has
been implicated in vascular disease in experimental
animals. Viral proteins are found in vascular lesions in
the lungs of patients with PAH, raising the possibility that
they participate in its pathogenesis. Adapted from [44]
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glycolysis for ATP generation and possibly
altering the apoptosis potential [48, 49]. Tyr-
osine kinase inhibitors (TKI) have been studied
for the treatment of PAH. Imatinib, a TKI used
for the treatment of CML is also a platelet-der-
ived growth factor (PDFR) receptor inhibitor
which showed initial improvement in clinical
end-points like World Health Organization
functional class (WHO-FC), 6MWDT and pul-
monary hemodynamics. Its use is limited due to
significant adverse effects reported with long--
term use, including syncope, worsening PAH in
4.9% of patients, and subdural hematoma in up
to 4.2% of patients receiving concomitant
anticoagulation [50]. Other TKIs (sorafenib and
dasatinib) have also been associated with
myocardial damage and worsening PAH
[51–53].
Inflammation and Thrombosis
Different inflammatory processes have been
associated with PAH, and the elevation of
inflammatory indicators such as C-reactive
protein (CRP), interleukin-1 beta, interleukin-6,
TNFa have been associated with worse outcome
in PAH [54, 55]. Endothelial dysfunction and
inflammation predispose to platelet aggregation
and in situ thrombosis. The shear stress or vas-
cular injury can induce up-regulation of cell
adhesion molecules that can attract inflamma-
tory mediators (monocytes/macrophages, lym-
phocytes) to endothelial cells which can
contribute to vascular remodeling. Use of anti-
coagulants has been shown to reduce the inci-
dence of thrombosis both in IPAH as well as
chronic thromboembolic PH [56, 57].
Vasoconstriction
Vasoconstriction is not a uniform process: there
is an imbalance of multiple vasoactive sub-
stances that lead to decreased relaxation of the
pulmonary vasculature, increasing the afterload
of the right ventricle. Early histopathologic
studies by Heath and Edwards in patients with
IPAH showed moderate medial hypertrophy,
concentric intimal fibrosis, vascular dilation
lesions, plexiform lesions and vascular necrosis.
This was later described as ‘‘vasospastic pul-
monary hypertension’’ present in children with
hyper-reactive lung vessels [58, 59]. This
mechanism was the foundation for the initial
treatment of patients with PAH.
Vascular remodeling in PAH will lead to
elevated pulmonary vascular resistance (PVR).
Normally, PVR drops by half within the first two
days of life in full-term newborns. Failure of
PVR to drop is associated with multiple factors
such as abnormal lung development, malde-
velopment of the pulmonary vasculature, pre-
mature delivery, mode of delivery, meconium
aspiration, maternal fever, maternal pulmonary
disease and maternal use of selective serotonin
update inhibitors [60–62]. In older children
with IPAH, intimal hyperplasia and occlusive
changes are found in pulmonary arterioles. In
contrast to adults, children have more smooth
muscle cell (SMC) hypertrophy, less intimal
fibrosis and fewer plexiform lesions. With
increasing age, intimal fibrosis and plexiform
lesions are more frequent.
There are three important pathways studied
in association with pulmonary vasoconstric-
tion: the nitric oxide pathway, the endothelin
pathway and the prostacyclin pathway.
a) Nitric oxide pathway: Nitric oxide (NO) is
synthesized in the endothelium by
endothelial nitric oxide synthase (eNOS),
playing an important role in regulating
vascular tone. NO then activates the
enzyme soluble guanylate cyclase (sGC)
which catalyzes the production of cyclic
guanosine monophosphate (cGMP), a sec-
ond messenger that results in activation of
cGMP-dependent protein kinases (PKGs),
triggering a cascade of reactions that lowers
intracellular calcium leading to vasodila-
tion. Phosphodiesterase 5 (PDE-5) lowers
cGMP levels in platelets and vascular
smooth muscle cells contributing to a pow-
erful negative feedback on NO/cGMP/PKG
signaling [63]. This sets the physiologic
ground for PDE-5 inhibitors. Some children
have increased expression of PDE5 enzyme,
leading to degradation of cGMP and vaso-
constriction [64]. PDE5 inhibitors replenish
cGMP and act as rescue agents preventing
rebound PAH while weaning inhaled NO,
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and also act as potent pulmonary vasodila-
tors [65]. Some forms of PAH have also
reduced bioavailability of endothelial NO,
either because of reduced eNOS expression
or secondary to oxidative stress leading to
vascular remodeling [66, 67]. There are
other substances that can also inhibit eNOS
production such as asymmetric dimethyl
arginine (ADMA) in infants with persistent
pulmonary hypertension [68].
b) Endothelin pathway: Endothelin (ET)-1, is a
potent vasoconstrictor. ET-1 acts via ETA
and ETB receptors on SMC. ETA receptors
are located on SMC where they mediate
vasoconstriction and ETB receptors are
located on both SMC and endothelial cells,
where they may mediate vasodilation or
vasoconstriction. There seems to be no
added advantage to selective ETA inhibi-
tion, suggesting that the relative expression
of the two receptors in disease states may
play a role in the pathogenesis PAH. High
circulating levels of ET-1 correlate with
disease severity in PAH patients. There is
upregulation of ETB receptors in patients
with PH associated with fibrogenesis and
cell proliferation [69].
c) Prostacyclin (PGI2) pathway: Prostacyclin is
synthesized in the arachidonic acid (AA)
pathway, by cyclooxygenase (COX) and
prostacyclin (PGI2) synthase. Prostacyclin
stimulates the PGI2 (IP) receptor on vascu-
lar smooth muscle cells, resulting in
increased intracellular cyclic adenosine
monophosphate (cAMP) and ultimately
vasodilation [70]. The vasodilatory effects
of prostacyclin were first described by Vane
et al. in 1976, initially referred as ‘‘prosta-
glandin X’’, they described its potent effect
on platelet aggregation and smooth muscle
relaxation [71]. PGI2 synthase levels are
decreased in patients with PAH leading to
an imbalance between AA and TXA2. PGI2
also inhibits thromboxane A2 (TXA2)
which is a potent vasoconstrictor and
platelet aggregator, and also has an impor-
tant anti-proliferative effect on the vascular
smooth muscle. Epoprostenol was the first
synthetic prostacyclin used in the treatment
of PAH and still remains as an important
therapeutic option in patients with severe
PAH [15, 72].
Molecular mechanisms of pulmonary
artery remodeling
The excessive vascular cell proliferation is a
feature common to all PH groups, affecting all
vessel layers leading to a decrease of the vessel
lumen which translates into higher right ven-
tricle afterload. ET-1 activates the mitogen-ac-
tivated protein kinase (MAPK) pathway, and
c-fos and c-jun genes that promote growth sig-
naling and control cell survival and differenti-
ation. PGI2 increases cAMP production which
inhibits myosin light chain kinase (MLCK)
leading to SMC relaxation. cAMP also has
anti-proliferative effects. The transforming
growth factor b (TGF-b) signaling pathway reg-
ulates cell growth and differentiation. Tran-
scription factors including hypoxia inducible
factor (Hif-1a), suppressor or cytokine signaling
3 (SOCS3) and nuclear factor kappa B (NF-jB)
are known regulators or pulmonary artery
smooth muscle cell (PASMC) proliferation.
Increased expression of Oct-4, a novel tran-
scription factor expressed in hypoxic cells and
pulmonary artery SMCs, is suggested to play an
important role in the development and pro-
gression of vascular remodeling. Notch-3 mRNA
regulates pulmonary arterial SMC homeostasis,
and this gene is overexpressed in PAH patients,
affecting SMC proliferation and vessel remod-
eling. DNA-binding protein inhibitors (Id)
family are another group of transcription fac-
tors that may act cooperatively in regulating
BMP-dependent SMC proliferation due to
chronic hypoxia. There are also epigenetic
modifications (histone modifications, DNA
methylation and RNA interference) that can
selectively activate or inactivate cell growth,
proliferations and apoptosis controlling genes.
This provides a different insight to the patho-
physiology of PAH leading to new treatment
strategies [73].
Right ventricular adaptation: The increased
afterload from pulmonary artery vasoconstric-
tion and vascular remodeling triggers compen-
satory RV mechanisms. The RV initially dilates
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and the muscle hypertrophies with preserved
systolic function. As the RV dilates, tricuspid
regurgitation (TR) increases related to tricuspid
valve annular dilation and valve non-coapta-
tion. There is RV volume overload and pressure
overload as PAH progresses affecting the inter-
ventricular interactions. There is also prolon-
gation of the RV ejection time beyond the LV
contraction, causing shifting of the interven-
tricular septum (IVS) toward the left ventricle in
both systole and diastole, affecting ventricular
filling, function and cardiac output.
CLINICAL PRESENTATION
Evaluation of infants and children with PAH is
always challenging. There are multiple areas of
development that must be taken into account
when evaluating children. This was well char-
acterized by the Pediatric Task Force of the
Pulmonary Vascular Research Institute (PVRI) in
Panama 2011, where a functional classification
for pediatric pulmonary hypertension was
developed, considering individual milestones
according to age [74]. Often, the signs and
symptoms of PAH are vague and may be treated
as other systemic disorders before evaluating for
PAH. Dyspnea and fatigue are the most frequent
symptoms in IPAH. Dyspnea occurs during
physical activity as a result of an inability to
increase cardiac output with increased oxygen
demand. In pediatrics, failure to thrive is con-
sidered as a red flag for chronic illness and is one
of the most important signs in children pre-
senting with IPAH. This is more noticeable in
children younger than 5 years of age who pre-
sent with growth impairment. Furthermore,
there is increased caloric expenditure and mal-
absorption in the context of cardiac cachexia
due to congestive heart failure [75]. Growth and
development are important tools to assess the
efficacy of therapy [75]. Children can present
with tachycardia and tachypnea as signs of
cardiac failure. Cyanosis at baseline or with
exertion is commonly seen in patients with
right to left shunts at baseline or shunts that
reverse with exertion due to increased right--
sided pressures. In IPAH, cyanosis occurs in the
presence of an atrial shunt. Chronic and
worsening cyanosis will lead to high hemat-
ocrit. Polycythemia is associated with head-
aches and increased risk of thrombosis.
Hemoptysis can occur secondary to clotting
disorders, pulmonary infarcts with secondary
arterial thrombosis, in patients with HHT, due
to pulmonary telangiectasia and, in some
patients, because of poorly monitored antico-
agulation therapy.
Children with severe right atrial enlargement
and increased right atrial pressure are at risk for
supraventricular arrhythmias (SVA). Patients
with SVA have a higher risk for clinical deteri-
oration and death, and therefore a history of
tachycardia or palpitations is important [76].
Syncope is an alarming sign of IPAH, more
common in children than in adults, being pre-
sent in up to 31% of children with IPAH [4].
Syncope is often post-exertional but often
reported when lifting up heavy objects. Syncope
is described as a poor prognostic factor in adult
PAH, it is often the initial presenting symptom
in children and may actually indicate vasore-
sponsiveness. Syncope may be manifest early in
the morning while waking up, or triggered by
inflammation or other vasoactive stimuli.
Peripheral vasodilation induced by exercise
possibly exacerbates this condition. Children
with IPAH have also been mistakenly treated for
seizure disorders, and these episodes are usually
associated with exercise when pulmonary pres-
sures rise significantly and, in the absence of
intracardiac shunting, cardiac output is com-
promised. Izzo et al. recently reported a case of a
4 year old with IPAH who was initially diag-
nosed as refractory nocturnal seizures. Noctur-
nal syncope is probably related to nocturnal
hypoxia associated with airway obstruction
which can also trigger a pulmonary hyperten-
sive crisis [4, 77, 78].
The clinical examination of a child with
IPAH can give many clues to the presence of RV
hypertension. A hyperdynamic RV is noted over
the precordial area in thin children, and it can
also be appreciated by palpating a right ven-
tricular heave at the right sternal border. Aus-
cultation findings include a normal first heart
sound (S1) and a loud pulmonary component of
the second heart sound (P2) with widening of
the second sound more noticeable with slower
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heart rates. In addition, there may be a RV S3 or
S4 gallop and a systolic click associated with a
dilated pulmonary artery. A holosystolic mur-
mur from tricuspid regurgitation (TR) is best
heard at the right lower sternal border. A sys-
tolic ejection murmur may be auscultated along
the left sternal border from flow across the
pulmonary valve and dilated main pulmonary
artery. A high-pitched early diastolic murmur of
pulmonary regurgitation may also be auscul-
tated in the left upper sternal border. Jugular
venous distention may be more prominent in
older children, reflecting increased right atrial
pressure. Patients with more overt signs of right
heart failure will present with hepatomegaly,
ascites, peripheral edema and weight loss
resulting from malabsorption due to bowel
edema.
DIAGNOSTIC EVALUATION
By definition, IPAH is a diagnosis of exclusion.
PAH is the common denominator for multiple
systemic disorders, and therefore a thorough
evaluation to diagnose potentially treat-
able conditions must be performed. This should
include a detailed history and physical exami-
nation, laboratory tests, noninvasive imaging
and invasive hemodynamic studies. A detailed
family history of pulmonary hypertension,
congenital heart disease, rheumatologic disor-
ders, other congenital anomalies, and unex-
plained deaths should be obtained. Recent
travel to high-altitude locations, a history of
anorexigenic drug use, and use of chemothera-
peutic agents like dasatinib, a tyrosine kinase
inhibitor which has been associated with PAH
[53].
The recommended diagnostic work-up for
children suspected of having IPAH is similar to
that for adults [15]. Pre- and post-ductal pulse
oximetry should be obtained when assessing an
infant with PAH, as a low post-ductal oxygen
saturation could indicate the presence of a right
to left ductal shunt, while a right to left atrial
shunt would give low pre- and post-ductal
saturations.
It is important to perform a complete diag-
nostic work-up to rule out all secondary causes
before making a diagnosis of IPAH. A compre-
hensive laboratory evaluation with thoughtful
clinical judgment should be made. Laboratory
testing includes baseline chemistries and more
specialized tests to rule out potential comor-
bidities in children with IPAH [15]. Pulmonary
hypertension in children often presents in
association with other syndromes, and they are
often difficult to classify into only one Group
[79]. Although Group I PAH encompasses dif-
ferent clinical presentations, they can share
similar histopathologic changes in the pul-
monary vasculature, allowing us to apply simi-
lar therapeutic approaches [80, 81].
Brain Natriuretic Peptide (BNP) is an impor-
tant biomarker in children with IPAH, used to
monitor response to therapy, progression of the
disease and mortality risk [82, 83]. BNP or B--
type natriuretic peptide, is synthesized in
response to volume expansion or pressure
overload in the ventricular myocardium. Its
precursor, pre-proBNP, is cleaved first to
proBNP, then to the biologically active BNP and
the inactive amino-terminal fragment
(NT-proBNP). BNP and NT-proBNP levels are
reasonably correlated in the clinical setting, but
they are measured by different assays and their
absolute numbers are not interchangeable.
NT-proBNP has a longer half-life in plasma
than BNP; therefore, NT-proBNP levels are gen-
erally higher than BNP and display less vari-
ability. NT-proBNP also appears to be more
affected by renal function than BNP [84].
BNP and NT-proBNP levels vary according to
age [85]. BNP values drop to adult levels by
2 weeks of life (45 pg/mL). In children with
PAH, BNP levels[180 pg/mL are associated with
decreased survival rate [83].
Serial measurements of BNP are beneficial in
predicting hemodynamic changes. BNP levels
have an inverse relationship with cardiac index
and a direct relationship with mean right atrial
pressure (mRAP), mean pulmonary artery pres-
sure (mPAP), pulmonary capillary wedge pres-
sure (PCWP) and pulmonary vascular resistance
(PVR) [83].
Other important diagnostic tests for the
evaluation of PAH include: echocardiography,
cardiac catheterization, 6-min walk test
(6MWT), cardiopulmonary exercise test,
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computerized tomography, magnetic resonance
and lung perfusion scan.
Echocardiography
The echocardiogram is the first line tool for the
diagnosis and follow-up of patients with PAH.
Echocardiography can provide an indirect
assessment of hemodynamics and both 2-D
imaging and Doppler echocardiography have
an important role in assessing structural
abnormalities and assessing myocardial func-
tion. Right atrial pressure (RAP) is often
assumed to be low, but patients with PAH often
have elevated RAP. Echocardiography can pro-
vide an estimated RAP by evaluating inferior
vena cava (IVC) distensibility. Long-axis inter-
rogation of the IVC from subcostal imaging,
1–2 cm from the RA junction, can predict ele-
vated RA pressures[10 mm Hg in PAH patients
with 89% sensitivity and 76% specificity using
the IVC distensibility index [86]. Right atrial
size assessment from the apical four-chamber
view can also be an important marker for
response to therapy and outcomes in PAH.
Tricuspid regurgitant jet velocity by contin-
uous wave Doppler is used to estimate RV sys-
tolic pressure using the modified Bernoulli
equation (RVSP-RAP = 4 V2), where V is TR jet
velocity, RVSP-RV the systolic pressure and RA
pressure is the right atrial pressure. The RAP is
usually not included in younger children as it is
only 0–5 mm Hg. Technical factors like an
incomplete spectral Doppler envelope can easily
underestimate PASP. Furthermore, estimated
PASP by Doppler can be significantly different
compared to right heart catheterization (RHC)
in 48% of cases [87].
Different orthogonal planes should be used
to assess RV size and function. As RV hyper-
tension worsens, RVH becomes prominent and
interventricular interactions are affected. As a
general rule, systolic septal flattening is consis-
tent with half-systemic PASP and systolic pos-
terior septal bowing into the LV is consistent
with supra-systemic PASP. The RV/LV end sys-
tolic diameter ratio can also assess septal shift
secondary to elevated RV pressure, with a RV/LV
ratio of[1 being associated with increased risk
for adverse events in children with PAH [88].
Other methods to assess RV function are tri-
cuspid annular plane systolic excursion
(TAPSE), myocardial performance index (MPI)
and strain imaging. TAPSE in children varies
according to age, and is an important marker of
RV longitudinal systolic function that can cor-
relate with response to therapy. Patients with
severe or longstanding PAH can also show
abnormal mitral and tricuspid inflow velocities,
reflecting diastolic dysfunction. Tissue Doppler
imaging can be abnormal in PAH and reflects
diastolic dysfunction [87]. Fractional area
change (FAC) is a surrogate of RV ejection
fraction; however, good-quality imaging of the
RV free wall is often difficult to obtain in older
children [89, 90]. When pulmonary regurgita-
tion (PR) is present, the mPAP can be estimated
by measuring the peak velocity of the PR jet.
Pulmonary vascular resistance (PVR) can be
estimated by measuring the peak TR velocity
and the ratio between RVOT (right ventricular
outflow tract) and VTI (velocity time integral),
which has been validated against RHC
[87, 91, 92]. Another novel method that corre-
lates with invasive hemodynamics is right ven-
tricle stroke work (RVSW), which can be
predictive of outcomes in children with PAH
[93].
Cardiac Catheterization
Right heart catheterization is the ‘‘gold stan-
dard’’ for diagnosis, evaluation of severity and
prognosis in PAH.
Diagnostic catheterization should include
acute vasodilator testing (AVT) with 20–80 parts
per million (ppm) of iNO. There are several
definitions for acute vasodilatory response.
Barst et al. defined acute vasodilatory response
as a reduction in mean PA pressure and PVR of
20%, with no change or increase in cardiac
output and a decreased or unchanged pul-
monary to systemic vascular resistance (Rp/Rs)
ratio [94]. Sitbon et al. defined response to AVT
as a drop in mean PAP by [10 mm Hg to
\40 mm Hg, and an increased or unchanged
cardiac output. The Sitbon criteria has shown
superiority in identifying patients with
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improved survival who will benefit from cal-
cium channel blockers therapy; however, it may
be difficult to use in younger children with
overall lower systemic and pulmonary pressures
[95]. A lower mPAP/mSAP and lower Rp/Rs ratio
is considered a better prognostic index in chil-
dren. Calcium channel blockers (CCBs) are
indicated in patients who are AVT responders.
Acute responders have less severe disease, as
demonstrated by a higher proportion of
patients in NYHA functional class I or II (47%
compared with 15% in nonresponders), a better
6MWT, lower PVR and higher survival. Those
who do not manifest a response to AVT are
unlikely to benefit from chronic oral CCBs, and
CCBs are contraindicated in them [15, 95–97].
Cardiac catheterization is overall a safe proce-
dure when performed at centers with expertise
in the care of PAH patients, with low compli-
cation rates (5.7%) and very low mortality
(0.2%) [98].
Cardiopulmonary Exercise Testing (CPET)
Children with pulmonary arterial hypertension
often have an exaggerated response of the pul-
monary vascular bed to exercise and to hypoxia
as compared with adults [99].
Children with IPAH have significant impair-
ment of aerobic capacity with significantly
lower peak oxygen consumption (VO2). Heart
rate, rhythm, oxygen saturation and blood
pressure are routinely recorded during CPET.
CPET is used to evaluate and follow-up children
with PAH. It is usually possible in children over
7 years of age using a bicycle ergometer or a
treadmill in taller children [100].
Six-Minute Walk Test (6MWT)
The 6MWT is a valuable and easy to perform
test in children with PAH. It records heart rate
and oxygen saturation at baseline and after
walking for 6 min in a safe environment. Dis-
tance walked and symptoms at the end of the
6 min are recorded. 6MWDT is most helpful
when done serially to assess response to ther-
apy. The 6MWT was able to accurately predict
peak oxygen consumption in children with
IPAH [101]. It is useful to assess functional
capacity and correlates with outcome in adults,
but it has not been standardized in children
with PAH [102].
Magnetic Resonance Imaging (MRI)
Although echocardiography is widely available,
MRI has become the gold standard for the
quantification of RV volume and RV function.
RV function is the main predictor of survival in
PAH patients. Cardiac MRI parameters such as
RV ejection fraction (RVEF) and left ventricular
stroke volume indexed (LVSVi) have been
associated with increased risk of death or
transplantation. Unfortunately, MRI often
requires longer scanning times and the use of
sedation or general anesthesia in children,
conditions which are not ideal in patients with
severe PAH who need close and continuous
monitoring [103–105].
Computerized Tomography (CT)
CT scanning time is shorter than MRI, and is
more readily available in most centers. A high
resolution CT can be considered when assessing
PAH in children, to rule out lung parenchymal
disorders including interstitial lung disease and
PVOD. CT angiography can detect pulmonary
venous stenosis, vascular malformations or the
presence of pulmonary thromboembolic dis-
ease. CT can be complementary to cardiac
catheterization, and in some instances it could
outline vascular anatomy with less radiation
exposure. One must always be conscious of the
stochastic effects of ionizing radiation. Children
with chronic illnesses such as PAH, chronic
lung disease and congenital heart disease are
often exposed to multiple X-rays throughout
their lives. The cumulative radiation dose to
which children are exposed is directly associ-
ated with a higher risk of cancer, especially in
younger children whose tissues are more
radiosensitive compared to adults. The ALARA
(as low as reasonably possible) principle should
always be the goal when performing CT in
children with PAH [15, 106–109].
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Ventilation/Perfusion Scan (V/Q Scan)
V/Q Scan is used to assess ventilation-perfusion
mismatch from airway or vascular obstruction,
and is most useful in the presence of pulmonary
embolism. V/Q Scans are challenging in chil-
dren as they require that a child be still for
several minutes after the inhalation of a
radioisotope and the injection of radioiso-
tope-tagged albumin, often requiring sedation
or anesthesia [15]. Although Group 4 PH is not
seen as often in children compared to adults,
thrombophilic disorders such as Protein C and
Protein S deficiency can present early in life or
in genetically predisposed teenage girls taking
estrogen containing contraceptives being at risk
for chronic pulmonary thromboembolic events
[110–113].
Other Testing
Polysomnography may be necessary to assess
for episodes of hypoxia and whether these epi-
sodes are predominantly obstructive, central, or
from mixed causes. A sleep study is also indi-
cated when patients show poor responsiveness
to PAH treatment. Pulmonary function testing
should be considered to asses for reversible lung
disease or airway abnormalities as well as for
follow-up evaluation [15].
BIOMARKERS
Novel biomarkers are being developed as we
continue to unveil the physiopathology of PAH.
The goal is to discover less invasive, sensitive
and accurate tests that can screen, diagnose and
correlate clinically in patients with PAH [114].
The analysis of biomarkers associated with
oxidative stress and also multiple metabolites,
including carbohydrates, lipids, nucleotides,
amino acids and amines, can become crucial for
a more comprehensive evaluation of PAH
[115–117]. Non-protein biomarkers like micro--
RNAs are associated with gene expression in
pulmonary vascular diseases. Other biomarkers
of endothelial damage are circulating endothe-
lial cells (CEC) and circulating progenitor cells
(CPC). CEC and CPC counts are elevated in
patients with PAH and may provide an estimate
of individual vascular competence that results
from the equilibrium between injury and repair
mechanisms, and may yield prognostic clues in
vascular diseases [118]. Future application of
biomarkers in children will likely offer new
understanding into the disease mechanisms of
PAH in children [13].
TREATMENT
Several advances have been made in the last two
decades for the treatment of IPAH. Currently,
there are 14 medications that have been
approved in adults for PAH. All PAH-specific
medications are used off-label in children. Since
the discovery of epoprostenol in the 1970s and
Food and Drug Administration (FDA) approval
for intravenous (IV) use in 1995, there has been
an important increase in survival rates in
patients with various types of PAH [3, 7, 15, 99].
Further research is still needed to assess the
benefit of all these medications in children.
General Treatment Measures
The primary care provider (PCP) plays an
invaluable role in the care of children with PAH.
All children with PAH presenting with fever,
respiratory infection and cardiac symptoms
require prompt evaluation. Children often have
a more reactive pulmonary vascular bed com-
pared to adults, and when not evaluated and
treated aggressively, alveolar hypoxia and sud-
den increase in pulmonary pressures can result
in a PH crisis.
Infants who are at risk for hospitalization
due to respiratory syncytial virus (RSV) infec-
tions should follow the American Academy of
Pediatrics guideline recommendations for pri-
mary prevention [119]. Annual influenza and
pneumococcal vaccination are also recom-
mended [15]. Antipyretics should be adminis-
tered for temperature elevations greater than
38 C (100.4 F) to minimize the consequences
of increased metabolic demands on an already
compromised cardio-respiratory system.
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Antitussive medications are also important
in children with PAH, as cough can increase
intrathoracic pressure, decreasing systemic
venous return and cardiac output leading to
syncope; this has been described as vasovagal
insufficiency in patients with PAH [120]. Anti-
tussive medications are also important in chil-
dren with PH after episodes of hemoptysis, to
prevent further bleeding. Decongestants such as
pseudoephedrine which are commonly found
in over-the-counter combinations should be
avoided as they may exacerbate the pulmonary
hypertension [121]. Constipation is also a
common problem in the pediatric population,
and it should be addressed promptly in patients
with PAH as Valsalva maneuvers can precipitate
syncopal episodes.
Anticoagulation
More than half of the autopsy specimens of
patients with IPAH show thrombi as a major
histologic feature. Consideration of chronic
anticoagulation in children with PAH is based
on studies in adults with IPAH. Warfarin has
been shown to be associated with improved
survival in adult patients [120]. Warfarin may
be considered in children with IPAH, patients
with low cardiac output, those with a long-term
indwelling catheter and those with hypercoag-
ulable states. The target goal international nor-
malized ratio (INR) for children with PAH is
between 1.5 and 2.0. Medication interactions
should also be taken into consideration when
patients are taking warfarin. Whether chronic
anticoagulation is efficacious as well as safe for
children with PAH remains to be determined
[15].
Inhaled Nitric Oxide (iNO)
Nitric oxide is used for AVT during right heart
catheterization, and for treating acute PAH cri-
sis in IPAH patients as well as following cardiac
surgery. iNO is the first choice therapy in
mechanically ventilated patients and can be
considered early as it has less impact on SVR
compared to systemic pulmonary vasodilators
[122]. iNO enhances ventilation-perfusion
matching, increasing blood flow to well-venti-
lated lung areas, compared to systemic
vasodilators which produce vasodilation in
areas of non-ventilated lung. Formation of
nitrogen dioxide (NO2) is dependent on iNO
concentration, with minimal production at
20 ppm of iNO. The most common adverse
effect is pulmonary edema from high concen-
trations of NO2 and methemoglobinemia,
which is also uncommon in patients breathing
NO at doses B80 ppm [123].
ADDITIONAL PHARMACOTHERAPY
Supplemental oxygen is reasonable to avoid
episodic or sustained hypoxemia with a target
oxygen saturation of 92–95% to prevent adverse
effects of hypoxia. Children with PAH may
require oxygen during sleep, during physical
activities for intracardiac shunting or during
flights. The use of supplemental oxygen during
airplane travel is reasonable, as most commer-
cial aircrafts are pressurized at 6000–8000 feet
(c. 1830–2440 m) above sea level, which could
lead to hypoxemia and subsequent elevation of
PAP [15, 124].
Prompt detection and management of
arrhythmias is essential as they can precipitate
an abrupt decrease in cardiac output and clini-
cal deterioration. Signs or symptoms of volume
overload can be managed with diuretics. Chil-
dren with decreased RV systolic function with
clinical signs of failure may benefit from digi-
talis (digoxin) 5 mcg/kg orally twice daily up to
10 years of age, then 5 mcg/kg once daily with a
maximum dose of 125 mcg per day. [15].
TARGETED THERAPY
The main goals of therapy in PAH are to
improve quality of life, improve hemodynam-
ics, halt the progression of disease and increase
life expectancy. Risk stratification for children
with PAH is important. Treatment goals may be
divided into those patients who are at lower or
higher risk for death. In adults, clinical evidence
of RV failure, worsening symptoms and elevated
BNP levels are associated with a higher risk of
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death. WHO-FC III-IV and failure to thrive in
children with PAH have been associated with
higher risk of death. Additional high-risk factors
include severe RV enlargement with decreased
ventricular function, pericardial effusion, mean
pulmonary artery pressure and mean systolic
arterial pressure (mPAP/mSAP) ratio[0.75, right
atrial pressure (RAP) [10 mmHg and PVRi
[20 wu/m2. A treatment algorithm was pre-
sented by the Pediatric Task Force of the 5th
World Symposium on Pulmonary Hypertension
(WSPH) in Nice, France (2013) [125]. (Fig. 2)
Targeted PH therapy is recommended based on
AVT and risk stratification of each patient.
There are four main groups of medications that
included calcium channel blockers, pros-
taglandin analogues, endotheling receptor
antagonis and PDE-5 inhibitors.
Calcium channel blockers (CCBs)
CCBs are recommended in children who
demonstrate a robust response to AVT. A sig-
nificantly greater percentage of children than
adults are acute responders (40 vs. 20%). Sur-
vival rates of children with IPAH at 1, 5, and
10 years were 97, 97, and 81%, respectively. for
acute responders (AR) on high-dose CCBs. Most
studies have used relatively high doses, e.g.,
long-acting nifedipine 120–240 mg daily or
amlodipine 20–40 mg daily; however, the opti-
mal dosing for children with IPAH is uncertain.
The pediatric guidelines recommend nifedipine
at a starting dose of 0.1–0.2 mg/kg orally three
times daily (TID), titrated to a dose range of
2–3 mg/kg/day; diltiazem, starting dose 0.5 mg/
kg orally TID, titrated to a dose range of 3–5 mg/
kg/day; and amlodipine, starting dose
0.1–0.3 mg/kg orally once daily, up to
2.5–7.5 mg orally once a day. Follow-up AVT is
important to determine responsiveness. Yung
et al., reported that close to half of the patients
who were responsive at initial catheterization
became unresponsive over a 10-year follow-up
period, increasing the risk of treatment failure
on CCB [4, 15, 16, 97].
Prostaglandins
Recognizing the effect of prostacyclin as a
pulmonary vasodilator has revolutionized ther-
apy for PAH, modifying the natural history of
IPAH. With the introduction of epoprostenol in
the post-prostanoid era, there have been major
improvements in life expectancy and quality of
life in both adults and children. Epoprostenol
Fig. 2 Treatment


















has been shown to improve hemodynamics,
quality of life, and exercise capacity in patients
with PAH. Chronic intravenous epoprostenol
lowers pulmonary artery pressure, increases
cardiac output, increases oxygen transport, and
improves exercise capacity, hemodynamics, and
survival in patients with IPAH [7, 97, 99, 126].
Epoprostenol (PGI2) is a potent vasodilator
of all vascular beds with proven efficacy in
patients with New York Heart Association
(NYHA) Class III or IV with IPAH. It is FDA-ap-
proved for patients above 18 years of age with
IPAH. Epoprostenol is a potent endogenous
inhibitor of platelet aggregation. It is adminis-
tered by continuous intravenous (IV) infusion
through a central line due to its very short
half-life of*6 min. Peripheral lines can be used
temporarily until central line is established.
There are two commercially available formula-
tions of epoprostenol. Epoprostenol is a more
thermo-sensitive solution and requires to be
stored at 2–8 C before use; once reconstituted is
only stable for 8 h on room temperature
(15–25 C), and therefore patients require to use
cold packs to keep the solution stable for 24 h. A
newer thermostable formulation is now avail-
able, which can be stored and infused at room
temperature (20–25 C), but still needs to be
protected from light. Patients are educated to
prepare their daily formulation at home.
Response to initial therapy is evaluated in a
hospital setting to monitor hemodynamic
effects, before chronic therapy is administered.
The initial dose is 1–2 ng/kg/min, titrated up to
a goal dose or dose-limiting side effects are
observed. The usual goal dose is between 50 and
80 ng/kg/min, reached within the first few
months. There is no maximum dose in chil-
dren, with some patients showing a propor-
tional dose-related response requiring doses
[100 ng/kg/min. Some of the most common
adverse effects of PGI2 are flushing, jaw pain,
foot and bone pain, headaches and diarrhea,
which are often well tolerated by children when
present. Meticulous care of the central line is
necessary to prevent associated complications
such as site and line infection, line thrombosis,
line occlusion and need for replacement. Pump
malfunction is another potential problem that
can lead to interruption of medication delivery,
and could lead to acute hemodynamic decom-
pensation. Therefore, a search for alternate
routes of drug delivery has led to the clinical
investigation of oral, inhaled, subcutaneous and
more stable and longer-acting intravenous
prostacyclin analogues [7, 15, 126].
Treprostinil is a longer-acting prostacyclin
analogue. It was initially approved by the FDA
in 2002 for parenteral use. Since then, newer
inhaled and oral formulations have been
approved for adults. The elimination half-life is
4.5 h, becoming a medication with a higher
safety profile compared to epoprostenol, but
abrupt withdrawal may also lead to rebound
pulmonary hypertension. The starting dose is
1–2 ng/kg/min, and a stable goal dose is usually
between 50 and 80 ng/kg/min according to the
pediatric guidelines. In practice, the treprostinil
dose is usually 1.5–2 times higher compared to
epoprostenol. Flushing, muscle pain, head-
aches, and diarrhea are also common side
effects, but less frequent compared to epopros-
tenol. Subcutaneous treprostinil has equivalent
pharmacokinetics to intravenous and is an
attractive option because of ease of administra-
tion not needing an indwelling intravenous
catheter. One of the most common adverse
effects is discomfort at the administration site,
which is less frequent in children compared to
adults [127, 128].
Inhaled treprostinil was approved in 2010 for
adults with PAH. Four times a day administra-
tion is recommended, often as part of combi-
nation therapy with PDE5 inhibitor and/or ET-1
receptor blocker. The goal dose is nine breaths
(54 ng) per treatment, four times a day. Inhaled
treprostinil is well tolerated in children with
IPAH, showing improvement in WHO func-
tional class, 6MWD and peak VO2. Some chil-
dren may have worsening of reactive airway
symptoms [15, 129]. Oral treprostinil was
approved in 2002 in extended release tablets,
and maximum dose is determined by tolerabil-
ity. Some adult patients with stable symptoms
and hemodynamics (WHO FC I or II with
baseline cardiac index[2.2 L/min/m2) on par-
enteral treprostinil could be transitioned to oral
treprostinil, a more convenient twice a day
dosing. There is limited experience in children
[130].
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Inhaled iloprost, a synthetic analogue of
prostacyclin, is an alternative in the acute set-
ting. It can be delivered rapidly and has less
systemic adverse effects compared to IV prosta-
cyclin. It has also been used to assess pulmonary
vasoreactivity in children with PAH. Iloprost
has a short half-life of 20–30 min, thus frequent
administration is needed (6–9 inhalations per
day). The addition of inhaled iloprost therapy
can reduce the need for IV prostanoid therapy
in some patients. Inhaled iloprost can trigger
reactive airway disease symptoms, which could
also limit or affect drug delivery to the lower
airway [15, 131].
Beraprost sodium, is an oral prostacyclin
analogue, whose potency is approximately 50%
that of epoprostenol. Initial studies showed a
good safety profile with improvement of func-
tional capacity and symptoms, but long-term
use at 12 months failed to show improvement
in exercise capacity assessed by 6MWT. It is not
approved for use in the United States [132, 133].
More recently, the oral prostacyclin receptor
(IP) agonist selexipag was FDA approved for the
management of adults with PAH. The density of
IP receptors varies among patients, with some
patients responding to low, medium or high
doses (up to 1600 mcg twice daily). Dose titra-
tion can be limited by side effects such as
headaches, diarrhea, nausea and jaw pain that
could lead to therapy discontinuation [134].
Endothelin receptor antagonists (ERA)
There are only oral formulations of ERA. Bosen-
tan is anoral nonselective ERA. It iswell tolerated
and effective in childrenwith PAH. Bosentan has
shown to improve WHO FC and survival in
children with PAH [135]. Bosentan serum con-
centration peaks 3–5 h after each dose, with a
terminal half-life of about 5 h. Bosentan dose
varies according to weight. For children\10 kg,
2 mg/kg twice daily is recommended; for chil-
dren 10-20 kg, 31.25 mg twice daily is recom-
mended; for children[20–40 kg, 62.5 mg twice
daily is recommended; and for children[40 kgm
125 mg twice daily is recommended. Bosentan
has a US Black Box Warning regarding hepato-
toxicity and teratogenicity. It is associated with
transaminase elevations (ALT or AST C3 times
upper limit of normal) and increased bilirubin
level. Monthly liver function tests (LFTs) are
required or at least every 2 weeks if LFTs are ele-
vated. Treatment should be stopped with any
clinical symptoms of hepatic injury or a serum
bilirubin C2 times the upper limit of normal,
while safety of reintroduction is unknown
[15, 133, 135–137].
Ambrisentan is a once a day selective ETA
receptor blocker. It has a terminal half-life of
*15 h. Children with PAH can be started at
2.5 mg (\20 kg) or 5 mg dose (C20 kg) and
considered for an up-titration to the 5–10 mg
dose. Ambrisentan has an acceptable safety
profile with less risk of hepatotoxicity. Routine
LFTs are recommended in children at baseline
and at periodic intervals. The most common
side effects are nasal congestion and headaches.
Ambrisentan has shown improvement of
WHO-FC and hemodynamics in children with
PAH, and some children can be safely switched
from bosentan to ambrisentan [138].
Macitentan is the newest oral endothelin
receptor blocker approved for adults with PAH
in October 2013. A single daily dose of 10 mg is
recommended for adults. This dose was shown
to reduce morbidity and mortality in patients
with PAH compared to placebo and a lower
daily dose of 3 mg [139]. Clinical trials are cur-
rently underway in children. Special education
for females who are taking ERA is required due
to its potential teratogenic effects. Pregnancy
must be excluded prior to starting therapy,
monthly throughout treatment and for 1
month after stopping ERA.
Phosphodiesterase 5 (PDE5) inhibitors
Sildenafil, a PDE5 inhibitor, is one of the front-
line medications for the treatment of IPAH in
children. Of historical importance, sildenafil was
approved by the FDA in June 2005 for the treat-
ment of adults with PAH. Subsequently, the
European Medicines Agency (EMA) approved
sildenafil for the treatment of pediatric patients
aged 1–17 years old with PAH in May 2011. In
August 2012, the FDA issued a warning against
the chronic use of sildenafil in children (ages
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1–17 years) with PAH based on the STARTS trial
results. The STARTS-I and II trial is a large ran-
domized, double-blind placebo-controlled study
of sildenafil as monotherapy. Patients were ran-
domized to placebo and low-, medium- and
high-dose sildenafil. After 3 years of follow-up,
20%of IPAHpatients in thehigh-dose groupdied
compared to 9% and 14% in the low- and med-
ium-dose groups, respectively. The higher mor-
tality reported in the high-dose group led to the
FDA warning. After further discussion with
experts in the field of pediatric PAH (PPHNET),
and more careful analysis of the results of the
STARTS trial, in March 2014, the FDA issued a
clarification statement, recognizing that there
may be situations in which the risk–benefit pro-
file of sildenafil may be acceptable in individual
children, and the medication should be admin-
istered by experienced physicians, at low doses
similar to the EMA in Europe [140].
Recommended doses are based on the results
of the STARTS-1 and STARTS-2 trials. The rec-
ommended dose for children\1 year of age is
0.5–1 mg/kg orally three times a day; for weight
\20 kg, 10 mg orally three times a day; and for
weight[20 kg, 20 mg orally three times a day.
Sildenafil serum levels peak at 1–2 h after oral
dose, which is important to know to monitor
for adverse effects such as hypotension, flush-
ing, nasal congestion, priapism and agitation.
Sildenafil is particularly beneficial in post-oper-
ative patients in preventing rebound PH at the
time of iNO withdrawal [141–145].
Tadalafil is a PDE5 inhibitor with similar
pharmacologic effects as sildenafil. Tadalafil has
a longer half-life of 15–17.5 h, allowing once a
day dosing. The starting dose is 0.5–1 mg/
kg/day, with a maximum dose of 40 mg orally
daily. Children can be safely switched to tada-
lafil from sildenafil, maintaining the clinical
effects of sildenafil [15, 129].
Combination Therapies
The approach to initiation of targeted therapy in
children with PAH is determined by the severity
of the disease and the symptomatic burden.
Adult trials, such as AMBITION, BREATH-2,
GRIPHON, SERAPHIN,COMPASS-2, have looked
at the benefits of using drug combination thera-
pies in PAH, looking at different end-points such
as WHO-FC and catheterization data. The ratio-
nale for upfront combination therapy is to
aggressively tackle different pathways involved
in the physiopathology of PAH and to attempt to
halt disease progression [134, 146, 147]. Patients
who are treated with dual or triple therapy tend
to have a higher WHO-FC and PVRi at diagnosis
than those treated withmonotherapy. Initiation
of prostacyclin therapy has been and remains the
cornerstone of management for patients with
WHO-FC IV. Formost patients who areWHO-FC
II or III at the time of diagnosis, oral agents such
as a PDE5 inhibitor or ERA are usually recom-
mended [47, 134, 147–150].
NOVEL THERAPIES IN PAH
Recent research is focusing on reversing the
molecular triggers that are unique to the RV and
promote decompensation at amuch earlier stage
than in the LV. There is a metabolic decompen-
sation with progressive RVH and increased RV
afterload, possibly driven by mitochondrial dys-
function and molecular signaling pathways that
can be targeted early and lead away from RV
failure. Patients with RVH have a higher expres-
sion of PDE-5 compared to patients with normal
RV myocardial cells; this is thought to cause a
direct positive inotropic effect in the RV, likely
due to cross-talk with the PDE-3 pathway.
Inflammation also plays an important role in the
pathogenesis of PAH. There is inhibition of reg-
ulatory T-cells, higher circulating interleukins
and growth factors that have been correlated
with worse prognosis in patients with PAH.
Cyclosporine,which inhibits theproduction and
release of IL-2, has been shown to cause regres-
sion of the degree of pulmonary artery remodel-
ing, pulmonary artery pressures, and RVH in
animal models. Etanercept, a potent anti-in-
flammatory agent and TNF-a inhibitor, reversed
vascular remodeling and improved hemody-
namics in preclinical models of PAH. Survivin is
an inhibitor of apoptosis and is highly expressed
in most cancers by growth factor signaling from
PDGF and EGF; in vivo models have shown
reversal of the disease in PAH [151].
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Tacrolimus (FK506) is a potent immunosup-
pressant that also potentiates the bone mor-
phogenic protein signaling pathway in
pulmonary arterial endothelial cells, promoting
vessel regeneration in PAH [152, 153].
The RhoA/Rho-kinase pathway plays an
important role in various fundamental cellular
functions, including contraction, motility, pro-
liferation, and apoptosis, leading to the devel-
opment of cardiovascular disease. Rho-kinase
activity is significantly increased in the PH
patients overall compared with controls. Fasu-
dil, a Rho-kinase inhibitor, inhibits vascular
smooth muscle cell contraction of pulmonary
arteries improving hemodynamics in IPAH
patients [154–156].
Pulmonary Artery Denervation (PADN)
PADN is a transcatheter procedure that can be
performed in patients with PAH who do not
respond to maximal medical therapy. Increased
neurohumoral activation in PAH leads to
increased circulating catecholamine levels,
abnormally high muscle sympathetic nerve
activity, and impaired heart rate variability,
which forms the theoretical basis of using
PADN. In an adult cohort of 66 patients, 56
patients at 1 year follow-up showed improve-
ment in mean PAP, cardiac output and PVR
[157, 158].
Blade-balloon Atrial Septostomy (BAS)
Atrial septostomy should be considered as a
palliative measurement in children with PAH
who present with recurrent syncope, chest pain
or severe RV failure despite maximal medical
therapy. Atrial septostomy is thought to protect
against syncope by allowing right to left
shunting at the atrial level, maintaining cardiac
output, particularly during a PH crisis. Patients
with mean right atrial pressure[20 mmHg and
with systemic arterial saturation\90% should
be carefully assessed, since BAS could lead to
massive atrial shunting and severe systemic
desaturation. BAS has also been described as a
safe palliative procedure as a bridge to recovery
or to lung transplantation [159–161].
Potts Shunt (PS)
PS is a palliative procedure done in patients
with supra-systemic RV pressures. It entails
creating a shunt between the left pulmonary
artery and the descending thoracic aorta,
avoiding brain and coronary hypoxia. PS should
be considered early in the clinical course, before
RV function progressively declines. PS decreases
RV afterload, improving interventricular inter-
actions, LV ejection fraction and ultimately
improving functional class. This can be con-
sidered as an alternative or as a bridge to lung
transplantation [162, 163].
Mechanical Support and Lung
Transplantation
Patients with PAH who present with hemody-
namic collapse might be candidates for car-
dio-respiratory mechanical support. Right
ventricular assist device and ECMO have been
implemented in PH patients as a bridge to
recovery or as a bridge to transplant [164].
IPAH is the second most common indication
for pediatric lung transplantation (LTx), which
comprises *9% of all transplanted patients,
most commonly in children aged 1–5 and
6–10 years. The observed survival in children is
similar to that of adult lung transplantation.
The median survival for infants and children up
to 10 years is 6–6.7 years; children 11–17 years
of age, have a lower survival at 4.6 years. Low
survival is usually related to chronic allograft
rejection. These children also encounter other
co-morbidities related to LTx such as hyper-
tension, renal dysfunction, hyperlipidemia, and
diabetes mellitus. Although pediatric LTx can
be considered as an option, there are very few
established pediatric LTx programs in the Uni-
ted States. Further research is needed to improve
outcomes and quality of life in this population
[165].
Pregnancy and PAH
Age-appropriate counseling to female teenagers
and parents of patients with PH should be car-
ried out regarding the effects of pregnancy and
Pulm Ther
teratogenic effects of some PH medications [15].
The hemodynamic and hormonal changes that
occur during pregnancy pose a higher risk of
mortality for patients with PAH. Maternal death
has been reported in 30% of women with IPAH
and up to 56% in women with secondary PH.
There are very few cases of women with IPAH
and successful pregnancy. Those who carried
out the pregnancy and survived had preterm
deliveries in half of the cases. These patients
also required prolonged hospitalization before




Despite the multiple advances in pediatric PAH
within the last two decades, much work is
needed to continue to improve long-term sur-
vival in children. Results of targeted combina-
tion therapeutic approaches are encouraging
but additional efforts toward preventing and
elucidating the complex mechanisms of PH in
the different group classifications are still nec-
essary. Bringing PAH awareness to the commu-
nity and to health-care providers is also
essential, providing the tools for early diagnosis
and prompt evaluation and referral of children
to pediatric PH centers for appropriate man-
agement to improve overall quality of life.
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